Diagnosis of hereditary transthyretin amyloidosis in patients with suspected chronic inflammatory demyelinating polyneuropathy unresponsive to intravenous immunoglobulins: results of a retrospective study
This study demonstrates that ATTRv should be investigated systematically in patients diagnosed with IVIg-NR CIDP. HCP-directed information campaigns are useful for modifying diagnostic practices.
Authors
- Jean‐Philippe Camdessanché (ORCID: https://orcid.org/0000-0002-5282-6707)
- Jean‐Baptiste Chanson (ORCID: https://orcid.org/0000-0003-4221-3840)
- Cyrla Hababou
- Guilhem Solé (ORCID: https://orcid.org/0000-0001-9599-6573)
- Yann Péréon (ORCID: https://orcid.org/0000-0002-0090-3571)
- Céline Tard (ORCID: https://orcid.org/0000-0002-6654-8090)
- Juliette Svahn (ORCID: https://orcid.org/0000-0002-2850-2374)
- Aïssatou Signaté (ORCID: https://orcid.org/0000-0001-7857-386X)
- Laurent Magy (ORCID: https://orcid.org/0000-0003-1784-2901)
- Shahram Attarian (ORCID: https://orcid.org/0000-0002-7211-4694)
- Pascal Cintas (ORCID: https://orcid.org/0000-0002-0242-4849)
- David Adams (ORCID: https://orcid.org/0000-0002-8722-4108)
Institutions
- Aix-Marseille Université (FR)
- Université Paris-Saclay (FR)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Centre Hospitalier Universitaire de Lille (FR)
- Centre Hospitalier Universitaire de Nantes (FR)
- Hospices Civils de Lyon (FR)
- Hôpital Pierre Wertheimer (FR)
- Hôpital Pellegrin (FR)
- Hôpital Nord (FR)
- Centre d'Investigation Clinique de Nantes (FR)
- Centre Hospitalier Universitaire de Martinique (MQ)
- Hôpital Universitaire Dupuytren (FR)
- Hôpitaux Universitaires de Strasbourg (FR)
- Hôpital Paule de Viguier (FR)
- Centre Hospitalier Universitaire de Saint-Étienne (FR)
- Université Lille Nord de France (FR)
Publication Details
- Journal
- Orphanet Journal of Rare Diseases
- Published
- 2025-03-01
- DOI
- https://doi.org/10.1186/s13023-025-03589-4
- Citations
- 4
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 3.22
Funders
- Alnylam Pharmaceuticals